SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

REACT

PROK·ProKidney
NEUTRAL
Drug Impact Rating7/10
Trial phase
Phase 3
Time to market
If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
Why 7/10
The single next hard, dated catalyst is the Phase 3 PROACT 1 topline data readout in Q2 2027 (~6-8 months away). This is a single-asset biotech and the readout is a make-or-break binary event for the stock, positive data would enable an accelerated-approval filing under the FDA's RMAT pathway, while negative data would likely render the company worthless. The impactScore of 7 reflects a high-concentration binary within ~6-12 months.
Actionable Insight NEUTRAL

The next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.

Price Chart

Loading chart...

Executive Summary

ProKidney (Nasdaq: PROK) is a late-clinical-stage cell therapy company developing REACT (rilparencel), a personalized autologous kidney-cell therapy for advanced chronic kidney disease (CKD) with type 2 diabetes. Positive Phase 2 data (July 2025) showed a 78% improvement in eGFR decline, and the FDA granted RMAT designation with an agreed accelerated-approval pathway using a single Phase 3 trial (PROACT 1). Enrollment for that trial completed in mid-2026, with topline data expected in Q2 2027. The stock trades at ~$1.41 with ~$182M cash funding operations into mid-2027. Analyst consensus is Buy with a mean $6.90 price target, but the stock is near its 52-week low, with high short interest (~13% of float) reflecting the binary nature of the Phase 3 readout. The KOL event on October 27, 2026 presents a near-term news event, but the defining catalyst remains the Phase 3 results over six months away.

How It Works

REACT is a personalized cell therapy made from the patient's own kidney cells. A small kidney biopsy is taken, the repair-oriented cells are multiplied in a lab, and then re-injected back into the patient's kidneys. These cells are thought to release regenerative signals that stabilize kidney function and slow disease progression. Because the cells come from the patient, no immune-suppressing drugs are needed.

Trial Status

The registrational Phase 3 PROACT 1 (REGEN-006) trial completed enrollment in mid-2026. It is evaluating bilateral injections of rilparencel in patients with Stage 3b/4 CKD and type 2 diabetes across over 70 clinical sites. Topline results are expected in Q2 2027. The Phase 2 REGEN-007 trial published positive results in the Clinical Journal of the American Society of Nephrology in January 2026. A second Phase 3 trial was halted as surplus to FDA approval requirements under the RMAT pathway.

The Two-Sided Case

▲ Bull Case6
Phase 2 REGEN-007 Group 1 showed a 78% improvement in annual eGFR decline (4.6 mL/min/1.73m², p<0.001), with a subgroup matching Phase 3 criteria showing 85% improvement, per July 2025 top-line results.
FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation and agreed to an accelerated approval pathway using eGFR slope as a surrogate endpoint, potentially enabling approval from a single Phase 3 trial.
PROACT 1 enrollment completed mid-2026 with topline results expected Q2 2027; cash of $181.6M (as of June 30, 2026) funds operations into mid-2027, covering the readout.
Analyst consensus rates the stock a Buy (5 Strong Buy, 4 Buy, 4 Hold, 1 Sell) with a mean price target of $6.90, roughly 390% upside from the $1.41 close.
Large institutional holders include Morgan Stanley ($20.1M), BlackRock ($10.6M), and Renaissance Technologies ($2.2M) as of Q2 2026 13F filings.
Addresses a massive unmet need: advanced CKD patients with type 2 diabetes who face limited options beyond dialysis or transplant.
▼ Bear Case6
Phase 2 REGEN-007 was small (n=24 in the lead Group 1) and open-label; one of two dosing groups (Group 2) missed statistical significance, raising questions about robustness.
Autologous cell therapy is complex and expensive to manufacture at scale since each dose is personalized from the patient's own kidney biopsy.
Director Brian Pereira sold ~$715K worth of shares in August 2026 at ~$1.42, according to SEC Form 4 filings.
Stock trades near its 52-week low of $1.30, down ~60% from the $3.48 high, reflecting skepticism about the binary Phase 3 readout.
Competition from well-established oral therapies (SGLT2 inhibitors like Farxiga, GLP-1 agonists like Ozempic) that already slow CKD progression.
High short interest of ~13.08% of float with 11 days to cover (as of Sep 30, 2026), signaling material bearish positioning.

Upcoming Catalysts

  • Virtual KOL event on October 27, 2026, recapping mechanism-of-action data from ASN Kidney Week and providing a corporate update
  • Q3 2026 earnings expected around November 9-10, 2026
  • Phase 3 PROACT 1 topline data readout, Q2 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ProKidney Press Release PROK ·Originating report

Sources · 12

Hover a chip for the title
1 investors.prokidney.com2 investors.prokidney.com3 investors.prokidney.com4 markets.businessinsider.com5 msn.com6 marketbeat.com7 prokidney.com8 prokidney.com9 biospace.com10 fiercebiotech.com11 stocktitan.net12 sec.gov